Research ExplorerPublicationsCancer specific mortality in patients with collecting duct v...

Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma

Standard

Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. / Panunzio, Andrea; Sorce, Gabriele; Tappero, Stefano; Hohenhorst, Lukas; Garcia, Cristina Cano; Piccinelli, Mattia; Tian, Zhe; Tafuri, Alessandro; De Cobelli, Ottavio; Chun, Felix K H; Tilki, Derya; Terrone, Carlo; Briganti, Alberto; Kapoor, Anil; Saad, Fred; Shariat, Shahrokh F; Cerruto, Maria Angela; Antonelli, Alessandro; Karakiewicz, Pierre I.

In: CANCER EPIDEMIOL, Vol. 82, 02.2023, p. 102297.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Panunzio, A, Sorce, G, Tappero, S, Hohenhorst, L, Garcia, CC, Piccinelli, M, Tian, Z, Tafuri, A, De Cobelli, O, Chun, FKH, Tilki, D, Terrone, C, Briganti, A, Kapoor, A, Saad, F, Shariat, SF, Cerruto, MA, Antonelli, A & Karakiewicz, PI 2023, 'Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma', CANCER EPIDEMIOL, vol. 82, pp. 102297. https://doi.org/10.1016/j.canep.2022.102297

APA

Panunzio, A., Sorce, G., Tappero, S., Hohenhorst, L., Garcia, C. C., Piccinelli, M., Tian, Z., Tafuri, A., De Cobelli, O., Chun, F. K. H., Tilki, D., Terrone, C., Briganti, A., Kapoor, A., Saad, F., Shariat, S. F., Cerruto, M. A., Antonelli, A., & Karakiewicz, P. I. (2023). Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. CANCER EPIDEMIOL, 82, 102297. https://doi.org/10.1016/j.canep.2022.102297

Vancouver

Panunzio A, Sorce G, Tappero S, Hohenhorst L, Garcia CC, Piccinelli M et al. Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. CANCER EPIDEMIOL. 2023 Feb;82:102297. https://doi.org/10.1016/j.canep.2022.102297

Bibtex

@article{e60c8483183e4766b25a6ae5b81b86fd,
title = "Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma",
abstract = "BACKGROUND: Collecting duct carcinoma (CDC) is biologically more aggressive than clear cell renal cell carcinoma (ccRCC). We tested for differences in cancer specific mortality (CSM) rates according to CDC vs. ISUP (International Society of Urological Pathology) 4 ccRCC histological subtype. We hypothesized that the survival disadvantage still applies, even after most detailed adjustments.METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 380 CDC vs. 6273 ISUP 4 ccRCC patients of all stages. Propensity score matching (age, sex, race/ethnicity, T, N, and M stages, nephrectomy, and systemic therapy status), Kaplan-Meier plots and multivariable Cox regression models were used.RESULTS: All 380 CDC were matched (1:2) with 760 ISUP4 ccRCC patients. Prior to matching CDC patients exhibited higher rates of lymph node invasion (37.6 % vs. 14.7 %, p < 0.001), and of distant metastases (40.8 % vs. 30.4 %, p < 0.001). Systemic therapy rates were higher in CDC (29.5 % vs. 20.5 %, p < 0.001). However, nephrectomy rates were higher in ISUP4 ccRCC patients (97.5 % vs. 84.7 %, p < 0.001). After matching, in multivariable Cox regression models addressing CSM, CDC was associated with a HR of 1.5 (p < 0.001) in the overall population vs. 1.9 (p = 0.014) in stage I-II vs. 1.4 (p = 0.022) in stage III vs. 1.6 in stage IV (p < 0.001), relative to ISUP4 ccRCC.CONCLUSION: CDC patients exhibited 40-90 % higher CSM than their ISUP4 ccRCC counterparts in the overall analysis, as well as in stage specific analyses. The CSM disadvantage applies despite higher rates of systemic therapy in CDC patients.",
keywords = "Humans, Carcinoma, Renal Cell/pathology, Kidney Neoplasms/pathology, Proportional Hazards Models, Lymph Nodes/pathology, Nephrectomy",
author = "Andrea Panunzio and Gabriele Sorce and Stefano Tappero and Lukas Hohenhorst and Garcia, {Cristina Cano} and Mattia Piccinelli and Zhe Tian and Alessandro Tafuri and {De Cobelli}, Ottavio and Chun, {Felix K H} and Derya Tilki and Carlo Terrone and Alberto Briganti and Anil Kapoor and Fred Saad and Shariat, {Shahrokh F} and Cerruto, {Maria Angela} and Alessandro Antonelli and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2022 Elsevier Ltd. All rights reserved.",
year = "2023",
month = feb,
doi = "10.1016/j.canep.2022.102297",
language = "English",
volume = "82",
pages = "102297",
journal = "CANCER EPIDEMIOL",
issn = "1877-7821",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma

AU - Panunzio, Andrea

AU - Sorce, Gabriele

AU - Tappero, Stefano

AU - Hohenhorst, Lukas

AU - Garcia, Cristina Cano

AU - Piccinelli, Mattia

AU - Tian, Zhe

AU - Tafuri, Alessandro

AU - De Cobelli, Ottavio

AU - Chun, Felix K H

AU - Tilki, Derya

AU - Terrone, Carlo

AU - Briganti, Alberto

AU - Kapoor, Anil

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Cerruto, Maria Angela

AU - Antonelli, Alessandro

AU - Karakiewicz, Pierre I

N1 - Copyright © 2022 Elsevier Ltd. All rights reserved.

PY - 2023/2

Y1 - 2023/2

N2 - BACKGROUND: Collecting duct carcinoma (CDC) is biologically more aggressive than clear cell renal cell carcinoma (ccRCC). We tested for differences in cancer specific mortality (CSM) rates according to CDC vs. ISUP (International Society of Urological Pathology) 4 ccRCC histological subtype. We hypothesized that the survival disadvantage still applies, even after most detailed adjustments.METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 380 CDC vs. 6273 ISUP 4 ccRCC patients of all stages. Propensity score matching (age, sex, race/ethnicity, T, N, and M stages, nephrectomy, and systemic therapy status), Kaplan-Meier plots and multivariable Cox regression models were used.RESULTS: All 380 CDC were matched (1:2) with 760 ISUP4 ccRCC patients. Prior to matching CDC patients exhibited higher rates of lymph node invasion (37.6 % vs. 14.7 %, p < 0.001), and of distant metastases (40.8 % vs. 30.4 %, p < 0.001). Systemic therapy rates were higher in CDC (29.5 % vs. 20.5 %, p < 0.001). However, nephrectomy rates were higher in ISUP4 ccRCC patients (97.5 % vs. 84.7 %, p < 0.001). After matching, in multivariable Cox regression models addressing CSM, CDC was associated with a HR of 1.5 (p < 0.001) in the overall population vs. 1.9 (p = 0.014) in stage I-II vs. 1.4 (p = 0.022) in stage III vs. 1.6 in stage IV (p < 0.001), relative to ISUP4 ccRCC.CONCLUSION: CDC patients exhibited 40-90 % higher CSM than their ISUP4 ccRCC counterparts in the overall analysis, as well as in stage specific analyses. The CSM disadvantage applies despite higher rates of systemic therapy in CDC patients.

AB - BACKGROUND: Collecting duct carcinoma (CDC) is biologically more aggressive than clear cell renal cell carcinoma (ccRCC). We tested for differences in cancer specific mortality (CSM) rates according to CDC vs. ISUP (International Society of Urological Pathology) 4 ccRCC histological subtype. We hypothesized that the survival disadvantage still applies, even after most detailed adjustments.METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 380 CDC vs. 6273 ISUP 4 ccRCC patients of all stages. Propensity score matching (age, sex, race/ethnicity, T, N, and M stages, nephrectomy, and systemic therapy status), Kaplan-Meier plots and multivariable Cox regression models were used.RESULTS: All 380 CDC were matched (1:2) with 760 ISUP4 ccRCC patients. Prior to matching CDC patients exhibited higher rates of lymph node invasion (37.6 % vs. 14.7 %, p < 0.001), and of distant metastases (40.8 % vs. 30.4 %, p < 0.001). Systemic therapy rates were higher in CDC (29.5 % vs. 20.5 %, p < 0.001). However, nephrectomy rates were higher in ISUP4 ccRCC patients (97.5 % vs. 84.7 %, p < 0.001). After matching, in multivariable Cox regression models addressing CSM, CDC was associated with a HR of 1.5 (p < 0.001) in the overall population vs. 1.9 (p = 0.014) in stage I-II vs. 1.4 (p = 0.022) in stage III vs. 1.6 in stage IV (p < 0.001), relative to ISUP4 ccRCC.CONCLUSION: CDC patients exhibited 40-90 % higher CSM than their ISUP4 ccRCC counterparts in the overall analysis, as well as in stage specific analyses. The CSM disadvantage applies despite higher rates of systemic therapy in CDC patients.

KW - Humans

KW - Carcinoma, Renal Cell/pathology

KW - Kidney Neoplasms/pathology

KW - Proportional Hazards Models

KW - Lymph Nodes/pathology

KW - Nephrectomy

U2 - 10.1016/j.canep.2022.102297

DO - 10.1016/j.canep.2022.102297

M3 - SCORING: Journal article

C2 - 36401949

VL - 82

SP - 102297

JO - CANCER EPIDEMIOL

JF - CANCER EPIDEMIOL

SN - 1877-7821

ER -